144 related articles for article (PubMed ID: 38512893)
41. High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy.
Castelli R; Ferraris L; Pantaleo G; Lambertenghi Deliliers G; Cicardi M
Dig Liver Dis; 2016 Nov; 48(11):1394-1397. PubMed ID: 27590841
[TBL] [Abstract][Full Text] [Related]
42. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.
Jiang XW; Ye JZ; Li YT; Li LJ
World J Gastroenterol; 2018 Jul; 24(28):3181-3191. PubMed ID: 30065564
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms.
Crespo J; Esteban R; Torres C; Oyagüez I; Casado MÁ; Buti M
Rev Esp Enferm Dig; 2017 Sep; 109(9):619-626. PubMed ID: 28648087
[TBL] [Abstract][Full Text] [Related]
44. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.
Pei SN; Chen CH
Leuk Lymphoma; 2015 Jun; 56(6):1611-8. PubMed ID: 25248874
[TBL] [Abstract][Full Text] [Related]
45. Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis.
Yao N; Fu S; Wu Y; Tian Z; Feng Y; Li J; Luo X; Yang Y; Ji F; Chen Y; Liu J; Zhao Y; Chen T
Acta Obstet Gynecol Scand; 2022 Nov; 101(11):1197-1206. PubMed ID: 36082797
[TBL] [Abstract][Full Text] [Related]
46. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
47. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy.
Méndez-Navarro J; Corey KE; Zheng H; Barlow LL; Jang JY; Lin W; Zhao H; Shao RX; McAfee SL; Chung RT
Liver Int; 2011 Mar; 31(3):330-9. PubMed ID: 20738779
[TBL] [Abstract][Full Text] [Related]
48. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
Buti M; Manzano ML; Morillas RM; García-Retortillo M; Martín L; Prieto M; Gutiérrez ML; Suárez E; Gómez Rubio M; López J; Castillo P; Rodríguez M; Zozaya JM; Simón MA; Morano LE; Calleja JL; Yébenes M; Esteban R
PLoS One; 2017; 12(9):e0184550. PubMed ID: 28898281
[TBL] [Abstract][Full Text] [Related]
49. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.
Mak JWY; Law AWH; Law KWT; Ho R; Cheung CKM; Law MF
World J Gastroenterol; 2023 Sep; 29(33):4942-4961. PubMed ID: 37731995
[TBL] [Abstract][Full Text] [Related]
50. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.
Idilman R; Arat M; Soydan E; Törüner M; Soykan I; Akbulut H; Arslan O; Ozcan M; Türkyilmaz AR; Bozdayi M; Karayalçin S; Van Thiel DH; Ozden A; Beksaç M; Akan H
J Viral Hepat; 2004 Mar; 11(2):141-7. PubMed ID: 14996349
[TBL] [Abstract][Full Text] [Related]
51. Introduction of routine hepatitis B screening for all patients receiving cancer treatment.
Leber K; Otten JMMB; Depla ACTM; Brandjes DPM; Lauw FN
Neth J Med; 2019 Jan; 77(1):19-24. PubMed ID: 30774100
[TBL] [Abstract][Full Text] [Related]
52. Hepatitis B screening before rituximab therapy: a multicentre South Australian study of adherence.
Hall SAL; Shaikh A; Teh K; Tantiongco M; Coghlan D; Karapetis CS; Chinnaratha MA; Woodman R; Muller KR; Wigg AJ
Intern Med J; 2018 Aug; 48(8):936-943. PubMed ID: 29345413
[TBL] [Abstract][Full Text] [Related]
53. Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand.
Laiwatthanapaisan R; Sripongpun P; Chamroonkul N; Dechaphunkul A; Sathitruangsak C; Sakdejayont S; Kongkamol C; Piratvisuth T
Clin Mol Hepatol; 2019 Dec; 25(4):366-373. PubMed ID: 31309773
[TBL] [Abstract][Full Text] [Related]
54. Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country.
Brakenhoff SM; Hoekstra R; Honkoop P; Roomer R; den Hollander JG; Bezemer G; de Knegt RJ; Sonneveld MJ; de Man RA
Eur J Intern Med; 2023 Feb; 108():68-73. PubMed ID: 36462966
[TBL] [Abstract][Full Text] [Related]
55. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G
Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466
[TBL] [Abstract][Full Text] [Related]
56. The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system.
Sun WC; Hsu PI; Yu HC; Lin KH; Tsay FW; Wang HM; Tsai TJ; Chen WC; Lai KH; Cheng JS
PLoS One; 2015; 10(2):e0116978. PubMed ID: 25658926
[TBL] [Abstract][Full Text] [Related]
57. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
Lalazar G; Rund D; Shouval D
Br J Haematol; 2007 Mar; 136(5):699-712. PubMed ID: 17338776
[TBL] [Abstract][Full Text] [Related]
58. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
[TBL] [Abstract][Full Text] [Related]
59. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis.
Xu Z; Dai W; Wu YT; Arshad B; Li X; Wu H; Chen HR; Wu KN; Kong LQ
Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12799. PubMed ID: 29265535
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis.
Im YR; Jagdish R; Leith D; Kim JU; Yoshida K; Majid A; Ge Y; Ndow G; Shimakawa Y; Lemoine M
Lancet Gastroenterol Hepatol; 2022 Oct; 7(10):932-942. PubMed ID: 35961359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
